290304-24-4

Basic information

• Product Name: Daun02
• Synonyms: Daun02;(8S,10S)-8-Acetyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-10-[[2,3,6-trideoxy-3-[[[[4-(beta-D-galactopyranosyloxy)-3-nitrophenyl]methoxy]carbonyl]amino]-alpha-L-lyxo-hexopyranosyl]oxy]-5,12-naphthacenedione
• CAS NO: 290304-24-4
• Molecular Formula: C₄₁H₄₄N₂O₂₀
• Molecular Weight: 884.78946
• Mol File: 290304-24-4.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 1128.4±65.0 °C(Predicted)
• Appearance: /
• Density: 1.67±0.1 g/cm3(Predicted)
• Solubility: insoluble in H2O; insoluble in EtOH; ≥17.92 mg/mL in DMSO with ultrasonic
• PKA: 7.39±0.60(Predicted)
• CAS DataBase Reference: Daun02(CAS DataBase Reference)
• NIST Chemistry Reference: Daun02(290304-24-4)
• EPA Substance Registry System: Daun02(290304-24-4)

Safety Data

• Hazardous Substances Data: 290304-24-4(Hazardous Substances Data)

Usage

Biological Activity

daun02 is an inhibitor of cell viability with ic50 values of 1.5μm, 3.5μm and 0.5μm, respectively in panc02, mcf-7 and t47-d cell lines [1].daun02, an anthracycline derivative, is a substrate of β-galactosidase. β-galactosidase catalyses daun02 into daunomycin, which causes apoptotic cell death and blockade of voltagedependent calcium channels. daun02 has been used in the study of suicide gene therapy which has thepotential to increase the selective toxicityof conventional antitumor agents. in this study, daun02 is shown to suppress the viability of several β-gal gene transduced tumor celllinesin vitro. however, none of thetumors responded to treatment withdaun02in vivo. this mayhave been due tothe limited aqueous solubilityof the agent.daun02 is also used to study activated neuronal ensembles in models of conditioned drug effects and relapse. the method is called daun02 inactivation method. in the fos–lacz transgenic rats, the previously drug activated neurons can be inactivated through injection of the prodrug daun02 [1,2].carl r. lupica, yavinshaham and bruce t. hope.new technologies for examining the role of neuronal ensembles in drug addiction and fear.nature reviews/neuroscience. 2013, 14: 743-754.

references

[1] david farquhar, bih fang pan, mamoru sakurai, ajitghosh, craig a. mullen, j. arly nelson. suicide gene therapy using e.coliβ-galactosidase. cancer chemotherpharmacol.2002, 50: 65–70.[2] fabio c. cruz, eisukekoya, danielle h. guez-barber, jennifer m. bossert,

Upstream product

• 290304-25-5 C₄₉H₅₂N₂O₂₄ 
• 3011-34-5 4-hydroxy-3-nitrobenzaldehyde 
• 121358-46-1 (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-formyl-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 290298-12-3 (2R,3S,4S,5R,6S)-2-(acetoxymethyl)-6-(4-(hydroxymethyl)-2-nitrophenoxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate 
• 3068-32-4 1-bromo-1-deoxy-2,3,4,6-tetra-O-acetyl-a-D-galactopyranoside 

Downstream Products

• 20830-81-3 DNR 
• 41833-13-0 4-hydroxymethyl-2-nitrophenol 

Relevant articles and documents

A daunorubicin β-galactoside prodrug for use in conjunction with gene- directed enzyme prodrug therapy

N-[4-(β-D-Galactopyranosyl)-3-nitrobenzyloxycarbonyl]daunomycin was synthesized as a neutral prodrug of daunomycin. Although stable in 0.05 M phosphate buffer, pH 7.4 at 37°C, it was rapidly converted to daunomycin and 3-nitro-4-hydroxybenzyl alcohol under the same conditions in the presence of E. coli β-galactosidase. (C) 2000 Elsevier Science Ltd.